Postoperative systemic adjuvant chemotherapy for bladder cancer.

Area of Science:

• Oncology
• Urology
• Clinical Pharmacology

Background:

• Bladder cancer necessitates effective adjuvant treatment post-cystectomy to improve patient outcomes.
• Adjuvant chemotherapy aims to reduce recurrence and metastasis in localized bladder cancer.
• Evaluating different chemotherapy regimens is crucial for optimizing treatment strategies.

Purpose of the Study:

• To compare the efficacy and toxicity of three adjuvant chemotherapy protocols in bladder cancer patients post-cystectomy.
• To assess the impact of different chemotherapy regimens on overall survival rates.
• To identify potential benefits of specific protocols in advanced disease stages.

Main Methods:

• Forty-six patients with non-metastatic bladder cancer received adjuvant chemotherapy (Protocols I, II, or III) after total cystectomy.
• Follow-up periods varied by protocol (18-43 months).
• Survival curves were analyzed and compared to historical controls; subgroup analysis for pT3/pT4 cases was performed.

Main Results:

• No statistically significant differences in survival were observed among the three protocols or versus historical controls for the overall patient population.
• In advanced pT3/pT4 cases, Protocol I showed a statistically significant survival advantage at 1 and 2 years compared to Protocol II and historical controls.
• Protocol I exhibited higher rates of gastrointestinal toxicity and myelosuppression; alopecia was common in Protocols I and II.

Conclusions:

• While overall survival benefits were not demonstrated, Protocol I (adriamycin, cyclophosphamide, cis-platinum) shows promise for advanced stage bladder cancer (pT3/pT4).
• Further investigation in a prospectively randomized trial is warranted to confirm the efficacy and safety of this combination regimen.
• Adjuvant chemotherapy regimens were generally well-tolerated, with no treatment-related deaths.